A Multiple Dose Trial Investigating Safety, Tolerability and Pharmacokinetics for Multiple Doses of NNC9204-1177 in Subjects Being Overweight or With Obesity

Trial Profile

A Multiple Dose Trial Investigating Safety, Tolerability and Pharmacokinetics for Multiple Doses of NNC9204-1177 in Subjects Being Overweight or With Obesity

Recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Nov 2017

At a glance

  • Drugs NN 9277 (Primary)
  • Indications Obesity
  • Focus Adverse reactions
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 07 Nov 2017 Planned End Date changed from 18 Dec 2018 to 23 Dec 2018.
    • 07 Nov 2017 Status changed from not yet recruiting to recruiting.
    • 17 Oct 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top